Denecimig (Mim8) prophylaxis in children with hemophilia A with or without factor VIII inhibitors
Research and Practice in Thrombosis and Haemostasis · 2026
DOI: 10.1016/j.rpth.2026.106914 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Research and Practice in Thrombosis and Haemostasis, 2026. Verfasst von Gili Kenet und 10 weiteren Autor:innen. Beteiligte Einrichtung: National Hemophilia Center and Institute of Thrombosis & Hemostasis, Sheba Medical Center, Tel-Hashomer, Israel. Hauptthemen laut MEDLINE: Hemophilia A, Factor VIII, Hemorrhage, Antibodies, Bispecific. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk A/S.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Denecimig (Mim8) is a next-generation activated factor (F)VIII mimetic bispecific antibody developed for subcutaneous prophylaxis in patients with hemophilia A (HA).
Objectives
This study evaluated 52-week outcomes with denecimig in children from the phase 3 FRONTIER3 study (NCT05306418).
Methods
Children aged 1 to 11 years with HA with or without FVIII inhibitors, received subcutaneous denecimig once every week (QW) for 26 weeks (Part 1). In Part 2, caregivers chose to continue QW or switch to once-every-month (QM) dosing for 26 weeks. Primary end point was the number of treatment-emergent adverse events. Assessed secondary outcomes included the number of treated bleeds and subtypes, injection-site reactions, antidenecimig antibodies, and caregiver-reported outcomes.
Results
All 70 enrolled participants completed Parts 1 and 2 of the study. During Part 2, 38 participants continued QW and 32 switched to QM. All treatment-emergent adverse events were mild/moderate, and none led to discontinuation. No thromboembolic events or clinical evidence of neutralizing antibodies were reported; injection-site reactions were infrequent (∼1% of injections). Estimated mean annualized bleeding rates for treated bleeds were 0.53 (Part 1, QW), 0.42 (Part 2, QW), 0.25 (Part 2, QM), and 0.50 (Parts 1 and 2, QW); 74% to 88% of participants had zero treated bleeds; no bleeds were reported in inhibitor-positive children with HA with inhibitors. All 10 baseline target joints resolved. Caregivers reported reduced treatment burden and improved physical functioning, and 98% of caregivers preferred denecimig to prior therapy.
Conclusion
Over 52 weeks, denecimig prophylaxis was well tolerated with no safety concerns and provided robust bleed protection, reduced treatment burden, and improved overall health-related quality of life in children with HA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Hemophilia Center and Institute of Thrombosis & Hemostasis, Sheba Medical Center, Tel-Hashomer, Israel.
- Gray Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Pediatric Hematology Department, Hospital San Joan de Déu, Esplugues de Llobregat, Spain.
- Department of Pediatric Hematology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
- Pediatric Hematology Unit, Hospital Dona Estefânia, ULS São José, Lisbon, Portugal.
- Onco-Hematology, Cell and Gene Therapy and Bone Marrow Transplant Clinic Area, Bambino Gesù Children's Hospital, Rome, Italy.
Förderung
- Novo Nordisk A/S
Zitieren
APA
Kenet, G., Berrueco, R., Fijnvandraat, K., Kjöllerström, P., Luciani, M., Mahlangu, J., Radhakrishnan, N., Wu, R., Páramo Florencio, A., Thaung Zaw, J. J., & Carcao, M. (2026). Denecimig (Mim8) prophylaxis in children with hemophilia A with or without factor VIII inhibitors. Research and Practice in Thrombosis and Haemostasis. https://doi.org/10.1016/j.rpth.2026.106914
Vancouver
Kenet G, Berrueco R, Fijnvandraat K, Kjöllerström P, Luciani M, Mahlangu J, et al. Denecimig (Mim8) prophylaxis in children with hemophilia A with or without factor VIII inhibitors. Research and Practice in Thrombosis and Haemostasis. 2026. doi:10.1016/j.rpth.2026.106914
BibTeX
@article{Kenet2026,
author = {Kenet, Gili and Berrueco, Rubén and Fijnvandraat, Karin and Kjöllerström, Paula and Luciani, Matteo and Mahlangu, Johnny and Radhakrishnan, Nita and Wu, Runhui and Páramo Florencio, Andrea and Thaung Zaw, Jay Jay and Carcao, Manuel},
title = {Denecimig (Mim8) prophylaxis in children with hemophilia A with or without factor VIII inhibitors},
journal = {Research and Practice in Thrombosis and Haemostasis},
year = {2026},
doi = {10.1016/j.rpth.2026.106914}
}
EUVIMED